

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-95 (canceled)

1 ~~96~~. (currently amended) An antibody that specifically binds to PSCA of SEQ ID NO. 2 ~~SEQ ID NO. 2~~ and which binds to a cell that expresses PSCA ~~protein and~~ protein and achieves an effect selected from the group consisting of:

- a. (a) kills the cell to which it specifically binds;
- b. (b) reduces tumor ~~burden~~ volume of a tumor which comprises cells that express PSCA of SEQ ID NO. 2, upon specific binding of the antibody to the cell;
- c. (c) is internalized within the cell to which it specifically binds; and/or
- d. (d) is cytostatic to the cell to which it specifically binds.

2 ~~97~~. (currently amended) An antibody of claim ~~96~~ which kills the cell to which it specifically binds.

3 ~~98~~. (currently amended) An antibody of claim ~~96~~ which is internalized within the cell to which it specifically binds.

4 ~~99~~. (currently amended) An antibody of claim ~~96~~ which is cytostatic to the cell to which it specifically binds.

5 ~~100~~. (previously presented) An antibody of claim ~~96~~ which is monoclonal.

6 ~~101~~. (previously presented) A hybridoma that produces the antibody of claim ~~100~~.

7/102. (previously presented) An antibody of claim ¹96, which is a human antibody.

8/103. (previously presented) An antibody of claim ¹96, which is a chimeric antibody.

9/104. (new) An antibody of claim ⁵100, which is humanized.

10/105. (new) An antibody of claim ¹96 that reduces tumor volume.